Phreesia (NYSE:PHR) Rating Increased to Strong-Buy at Wall Street Zen

Phreesia (NYSE:PHR) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the company. Robert W. Baird decreased their price objective on Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, December 10th. Zacks Research downgraded shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada began coverage on shares of Phreesia in a research report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price objective on the stock. DA Davidson dropped their price objective on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Canaccord Genuity Group decreased their target price on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, December 9th. Seventeen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average price target of $29.76.

Phreesia Stock Performance

Shares of PHR stock opened at $13.41 on Friday. The stock’s 50-day moving average is $17.18 and its two-hundred day moving average is $22.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia has a 1 year low of $13.40 and a 1 year high of $32.76. The firm has a market cap of $808.49 million, a price-to-earnings ratio of -134.09 and a beta of 0.61.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The firm had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business’s revenue was up 12.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) EPS. Analysts predict that Phreesia will post -1.1 earnings per share for the current year.

Insider Buying and Selling

In other news, General Counsel Allison C. Hoffman sold 3,995 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $65,358.20. Following the completion of the sale, the general counsel directly owned 169,661 shares of the company’s stock, valued at $2,775,653.96. This trade represents a 2.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,202 shares of Phreesia stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $36,024.72. Following the completion of the sale, the senior vice president owned 157,349 shares in the company, valued at approximately $2,574,229.64. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 60,766 shares of company stock worth $1,013,817 in the last three months. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently bought and sold shares of PHR. Federated Hermes Inc. acquired a new position in shares of Phreesia during the 3rd quarter worth $32,000. Asset Management One Co. Ltd. purchased a new stake in Phreesia during the third quarter worth about $45,000. Farther Finance Advisors LLC grew its position in Phreesia by 9,375.0% during the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock worth $86,000 after buying an additional 3,000 shares during the period. KBC Group NV increased its holdings in Phreesia by 83.4% in the fourth quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after buying an additional 1,568 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in Phreesia in the third quarter valued at about $83,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.